Company Overview and News

 
JSW Steel hits record high

18h thehindubusinessline
Shares of JSW Steel today hit a life-high as the Competition Commission of India has found no adverse effect on competition from Bhushan deal. The stock hit a record high, rising as much as 2.5 per cent to Rs 427.55.
YESBANK 500470 TTST TATASTEEL TATLY 500228 BHUSANSTL 532648 YYBKY JSWSTEEL 500055

 
Positive on auto, steel, HFCs but don#39;t see long-term opportunity in OMCs: Emkay Global

20h moneycontrol
The market rebounded on Friday with the Sensex rising nearly 300 points intraday after losing about 1,000 points in previous three sessions.
YESBANK EMKAY 500228 532737 532648 YYBKY JSWSTEEL

 
ArcelorMittal gets CCI nod for Essar Steel acquisition

2018-09-21 freepressjournal.in
New Delhi : The Competition Commission has approved the acquisition of debt-ridden Essar Steel by a consortium of ArcelorMittal and Japan’s Nippon Steel & Sumitomo Metal Corporation.
500228 JSWSTEEL

 
CCI approves ArcelorMittal’s acquisition of Essar Steel

2018-09-20 livemint
New Delhi: The Competition Commission of India (CCI has approved the acquisition of debt-ridden Essar Steel by a consortium of ArcelorMittal and Japan’s Nippon Steel & Sumitomo Metal Corporation.
500228 JSWSTEEL

 
CCI approves ArcelorMittal#39;s acquisition of Essar Steel

2018-09-20 moneycontrol
The Competition Commission has approved the acquisition of debt-ridden Essar Steel by a consortium of ArcelorMittal and Japan's Nippon Steel & Sumitomo Metal Corporation.
500228 JSWSTEEL

 
Coal import scam: Adani group gets interim relief from DRI

2018-09-19 moneycontrol
The Bombay High Court on Wednesday granted interim relief to the Adani group by restraining the Directorate of Revenue Intelligence (DRI) from giving effect to the letters rogatory (LRs) issued to several countries against three group companies in an alleged case of overvaluation of Indonesian coal imports in the past.
ANNRY ADANIENT 500228 INDIACEM 530005 512599 JSWSTEEL JSWENERGY 533148

 
Metal stocks shine as govt plans to hike steel import duty

2018-09-19 thehindubusinessline
Shares of metal companies jumped after Reuters reported that the government is considering raising the import duty on steel to support rupee. Nifty metal index rose as much 2.1 per cent, its biggest gain in nearly a week
HNDNF 500470 HINDALCO TTST TATASTEEL TATLY 500228 500440 JSWSTEEL

 
D-Street Buzz: Nifty metal outperforms led by JSW Steel; Dish TV down 6%, BoB most active

2018-09-19 moneycontrol
The Indian benchmark indices continues to trade on a positive note this Wednesday afternoon with the Nifty50 up 21 points and is trading at 11,300 while the Sensex is trading higher by 53 points at 37,343.
HINDCOPPER KOHINOOR MUTHOOTFIN PGEL 500325 500228 RELIANCE 532617 HNDZY HFCL 533398 NAUKRI 532777 533137 HCL-INSYS DEN 532221 500470 SONATSOFTW RIGD 500179 JSL GAILF BEL RLNIY SBAZ BHQRY HINDALCO 532508 533581 513599 JETAIRWAYS JSWSTEEL 533104 512559 HNDNF 500183 TTST TATASTEEL TATLY GAILY DCMSHRIRAM 500049 GLOBUSSPR 500440 500188 HINDZINC 523367

 
JSW Steel touches 52-week high as Nomura initiates buy with target Rs 484

2018-09-19 moneycontrol
Shares of JSW Steel touched 52-week high of Rs 423.30, rising more than 4 percent intraday Wednesday after broking house Nomura initiated buy on the stock.
500228 JSWSTEEL

 
Deals Buzz: Five bidders including JSW for Usha Martin’s steel business

2018-09-19 livemint
Deals Buzz brings to you, your dose of the top deals news reported from newsrooms across the country
USHAMART 517146 500470 TTST LAKSHVILAS TATASTEEL TATLY 534690 500228 UHBTY JSWSTEEL

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...